Literature DB >> 26861001

Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs.

Sonja Vuč Ković1, Katarina Savić Vujović, Dragana Srebro, Branislava Medić, Tatjana Ilic-Mostic.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of pain, inflamation and fever. They are usually well tolerated in healthy persons, but in patients with risk factors (advanced age, renal impairment, heart failure, liver disease, concurrent medications with antihypertensive drugs), NSAIDs can induce serious renal adverse effects. They include sodium and water retention with edema, worsening of heart failure, hypertension, hyponatremia, hyperkalemia, acute kidney injury, chronic kidney disease, renal papillary necrosis and acute interstitial nephritis. The majority of these adverse effects are due to the inhibition of prostaglandins synthesis and they are dose and duration-dependent. Acute forms of kidney injuries are transient and often reversible upon drug withdrawal. Chronic use of NSAIDs in some patients may result in chronic kidney disease. It is recommended that patients at risk should have preventative strategies in place, including the use of the "lowest effective dose" of NSAID for the "shortest possible time" and monitoring renal function, fluid retention and electrolyte abnormalities. Patients who are taking antihypertensive medications should be monitored for high blood pressure and the doses of antihypertensive medications should be adjusted if needed. In general, the combination of NSAIDs and angiotensin inhibitors should be avoided. Some other preventive measures are dietary salt restriction, use of topical NSAIDs/non-pharmacological therapies and use of calcium channel blockers for treating hypertension.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26861001     DOI: 10.2174/0929867323666160210125920

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  [Side effects of pain therapy : Sufficient analgesia without unnecessary complications].

Authors:  F Greul; A Zimmer; W Meißner
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

2.  Protective effect of cilastatin against diclofenac-induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters.

Authors:  Xiaokui Huo; Qiang Meng; Changyuan Wang; Jingjing Wu; Chong Wang; Yanna Zhu; Xiaodong Ma; Huijun Sun; Kexin Liu
Journal:  Br J Pharmacol       Date:  2020-03-05       Impact factor: 8.739

3.  In Vivo Osteoinduction: Evaluating 2-Beta Coxatene as an Immunoinductive Compound and Novel Ingredient for Joint Support.

Authors:  Katherine Spinks; James J Scaffidi
Journal:  Integr Med (Encinitas)       Date:  2016-10

Review 4.  Cannabinoids and Pain: New Insights From Old Molecules.

Authors:  Sonja Vučković; Dragana Srebro; Katarina Savić Vujović; Čedomir Vučetić; Milica Prostran
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

5.  Antenatal exposure to nonsteroidal anti-inflammatory drugs and risk of neonatal hypertension.

Authors:  Mounira Habli; Corey C Clifford; Tammy M Brady; Zahidee Rodriguez; Michaela Eschenbacher; Malcolm Wu; Emily DeFranco; James Gresh; Beena D Kamath-Rayne
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-07-27       Impact factor: 3.738

Review 6.  Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis.

Authors:  John Burke; Monte Hunter; Ravindra Kolhe; Carlos Isales; Mark Hamrick; Sadanand Fulzele
Journal:  Clin Transl Med       Date:  2016-08-10

7.  Assessing the negative impact of phenyl alkanoic acid derivative, a frequently prescribed drug for the suppression of pain and inflammation, on the differentiation and proliferation of chondrocytes.

Authors:  Seyit Ali Gumustas; İbrahim Yilmaz; Mehmet Isyar; Duygu Yasar Sirin; Ahmet Guray Batmaz; Ali Akin Ugras; Kadir Oznam; Zafer Ciftci; Mahir Mahirogullari
Journal:  J Orthop Surg Res       Date:  2016-06-30       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.